These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37388717)

  • 41. Safety of non-hormonal medications for managing hot flashes.
    De Franciscis P; Guida M; Schiattarella A; Riemma G; Colacurci N
    Expert Opin Drug Saf; 2022 Feb; 21(2):215-221. PubMed ID: 34304686
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Comprehensive Method To Quantify Adaptations by Male and Female Mice With Hot Flashes Induced by the Neurokinin B Receptor Agonist Senktide.
    Krull AA; Larsen SA; Clifton DK; Neal-Perry G; Steiner RA
    Endocrinology; 2017 Oct; 158(10):3259-3268. PubMed ID: 28531316
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protocol for systematic review and meta-analysis: hop (Humulus lupulus L.) for menopausal vasomotor symptoms.
    Abdi F; Kazemi F; Ramezani Tehrani F; Roozbeh N
    BMJ Open; 2016 Apr; 6(4):e010734. PubMed ID: 27105715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition.
    Randolph JF; Sowers M; Bondarenko I; Gold EB; Greendale GA; Bromberger JT; Brockwell SE; Matthews KA
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6106-12. PubMed ID: 16144949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A review of paroxetine for the treatment of vasomotor symptoms.
    Slaton RM; Champion MN; Palmore KB
    J Pharm Pract; 2015 Jun; 28(3):266-74. PubMed ID: 25107421
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vasomotor symptoms and neurovegetative comorbidities on the menopause: insights from an Italian quantitative research.
    Graziottin A; Banerji V; Hall G
    Gynecol Endocrinol; 2019 Sep; 35(9):762-766. PubMed ID: 31266379
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women.
    Skorupskaite K; George JT; Veldhuis JD; Millar RP; Anderson RA
    Neuroendocrinology; 2018; 106(2):148-157. PubMed ID: 28380486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of Menopausal Symptoms: A Review.
    Crandall CJ; Mehta JM; Manson JE
    JAMA; 2023 Feb; 329(5):405-420. PubMed ID: 36749328
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-hormonal treatment strategies for vasomotor symptoms: a critical review.
    Hall E; Frey BN; Soares CN
    Drugs; 2011 Feb; 71(3):287-304. PubMed ID: 21319867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Nonhormonal Treatment for Moderate to Severe Vasomotor Symptoms of Menopause.
    Fantasia HC
    Nurs Womens Health; 2016; 20(5):511-518. PubMed ID: 27719781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of nulliparity, hypertensive disorders of pregnancy, and gestational diabetes on vasomotor symptoms in midlife women.
    Cortés YI; Conant R; Catov JM; Matthews KA; Crawford SL; Hedderson MM; Thurston RC
    Menopause; 2020 Dec; 27(12):1363-1370. PubMed ID: 32796290
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resistance training reduced luteinising hormone levels in postmenopausal women in a substudy of a randomised controlled clinical trial: A clue to how resistance training reduced vasomotor symptoms.
    Nilsson S; Henriksson M; Berin E; Engblom D; Holm AS; Hammar M
    PLoS One; 2022; 17(5):e0267613. PubMed ID: 35617333
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vasomotor Symptoms Across the Menopause Transition: Differences Among Women.
    Avis NE; Crawford SL; Green R
    Obstet Gynecol Clin North Am; 2018 Dec; 45(4):629-640. PubMed ID: 30401547
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research.
    Rani P; Zehra D; Mansoor M; Rani P
    Arch Womens Ment Health; 2024 Mar; ():. PubMed ID: 38478035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Shared genetic influences on depression and menopause symptoms.
    Meijsen JJ; Shen H; Vemuri M; Rasgon NL; Koenen KC; Duncan LE
    Psychol Med; 2023 Apr; 53(6):2241-2251. PubMed ID: 34865661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hormonal and nonhormonal treatment of vasomotor symptoms.
    Krause MS; Nakajima ST
    Obstet Gynecol Clin North Am; 2015 Mar; 42(1):163-79. PubMed ID: 25681847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidemiology and treatment patterns of UK women diagnosed with vasomotor symptoms: Findings from the Clinical Practice Research Datalink GOLD database.
    Kiran A; Schultz NM; Siddiqui E; Todorova L; Van der Poel B; Stoelzel M; Robinson L
    Maturitas; 2022 Oct; 164():1-8. PubMed ID: 35738198
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies.
    Zhu D; Chung HF; Dobson AJ; Pandeya N; Anderson DJ; Kuh D; Hardy R; Brunner EJ; Avis NE; Gold EB; El Khoudary SR; Crawford SL; Mishra GD
    Am J Obstet Gynecol; 2020 Dec; 223(6):898.e1-898.e16. PubMed ID: 32585222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of vasomotor symptoms in the menopausal transition and postmenopausally: psychiatric comorbidity.
    Alexander JL; Burger H; Dennerstein L; Woods NF; Davis SR; Kotz K; Van Winkle J; Richardson G; Ratka A; Kessel B
    Expert Rev Neurother; 2007 Nov; 7(11 Suppl):S115-37. PubMed ID: 18039061
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vasomotor and sexual symptoms in older Australian women: a cross-sectional study.
    Zeleke BM; Bell RJ; Billah B; Davis SR
    Fertil Steril; 2016 Jan; 105(1):149-55.e1. PubMed ID: 26450529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.